Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Non-Current Debt: 2018-2025

  • Dr Reddys Laboratories' Non-Current Debt rose 27.78% to $92.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $92.0 million, marking a year-over-year increase of 27.78%. This contributed to the annual value of $92.0 million for FY2025, which is 27.78% up from last year.
  • According to the latest figures from Q1 2025, Dr Reddys Laboratories' Non-Current Debt is $92.0 million, which was up 27.78% from $72.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' Non-Current Debt's 5-year high stood at $92.0 million during Q1 2025, with a 5-year trough of $16.0 million in Q1 2023.
  • For the 3-year period, Dr Reddys Laboratories' Non-Current Debt averaged around $60.0 million, with its median value being $72.0 million (2024).
  • Per our database at Business Quant, Dr Reddys Laboratories' Non-Current Debt surged by 405.88% in 2021 and then tumbled by 78.95% in 2023.
  • Over the past 5 years, Dr Reddys Laboratories' Non-Current Debt (Quarterly) stood at $86.0 million in 2021, then declined by 11.63% to $76.0 million in 2022, then tumbled by 78.95% to $16.0 million in 2023, then skyrocketed by 350.00% to $72.0 million in 2024, then climbed by 27.78% to $92.0 million in 2025.
  • Its Non-Current Debt was $92.0 million in Q1 2025, compared to $72.0 million in Q1 2024 and $16.0 million in Q1 2023.